SCHEMBL7710751

SCHEMBL7710751

CC1Oc2ccc(C(Cc3ccc(S(N)(=O)=O)cc3)NC(=O)OC(C)(C)C)cc2N=C1N

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 11/20 0.41
CA1 P00915 7/20 0.40
CA9 Q16790 3/20 0.40
CA4 P22748 1/20 0.40
CA7 P43166 1/20 0.40
PTPRB P23467 5/20 0.38
ALDH1A1 P00352 4/20 0.38
HPGD P15428 4/20 0.38
HTT P42858 4/20 0.38
NPSR1 Q6W5P4 4/20 0.38
LMNA P02545 3/20 0.38
PKM P14618 3/20 0.38
HSD17B10 Q99714 3/20 0.38
TSHR P16473 2/20 0.38
TP53 P04637 2/20 0.38
MAPT P10636 1/20 0.38
AGTR1 P30556 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7713438 0.93 PTPRB (0.38) CA2PTPRBALDH1A1HPGDHTT
SCHEMBL7711369 0.91 ALDH1A1 (0.37) PTPRBALDH1A1HPGDHTTNPSR1
SCHEMBL7708193 0.90 ALDH1A1 (0.38) PTPRBALDH1A1HPGDHTTNPSR1
SCHEMBL7704969 0.89 ALDH1A1 (0.36) PTPRBALDH1A1HPGDHTTNPSR1
SCHEMBL7708356 0.89 CTSS (0.41) PTPRBALDH1A1HPGDHTTNPSR1
SCHEMBL7704912 0.89 ALDH1A1 (0.45) ALDH1A1HPGDHTTNPSR1LMNA
SCHEMBL7704948 0.88 SMN1; SMN2 (0.40) PTPRBALDH1A1HPGDHTTNPSR1
SCHEMBL7708354 0.88 PPARG (0.39) PTPRBALDH1A1HPGDHTTNPSR1
SCHEMBL7711330 0.87 CTSS (0.36) PTPRBALDH1A1HPGDHTTNPSR1
SCHEMBL7711460 0.86 ALDH1A1 (0.34) PTPRBALDH1A1HPGDHTTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed